Fintel reports that Fmr has filed a 13G/A form with the SEC disclosing ownership of 7.05MM shares of Allovir Inc (ALVR). This represents 7.563% of the company.
In their previous filing dated February 9, 2022 they reported 7.38MM shares and 11.33% of the company, a decrease in shares of 4.53% and a decrease in total ownership of 3.77% (calculated as current - previous percent ownership).
Analyst Price Forecast Suggests 343.29% Upside
As of February 8, 2023, the average one-year price target for Allovir is $26.78. The forecasts range from a low of $23.23 to a high of $31.50. The average price target represents an increase of 343.29% from its latest reported closing price of $6.04.
The projected annual revenue for Allovir is $0MM, a decrease of �%. The projected annual EPS is -$2.28.
What is the Fund Sentiment?
There are 216 funds or institutions reporting positions in Allovir. This is a decrease of 31 owner(s) or 12.55% in the last quarter. Average portfolio weight of all funds dedicated to ALVR is 0.04%, an increase of 99.51%. Total shares owned by institutions increased in the last three months by 34.48% to 42,385K shares. The put/call ratio of ALVR is 0.46, indicating a bullish outlook.
What are large shareholders doing?
Artal Group holds 5,577K shares representing 6.17% ownership of the company. In it's prior filing, the firm reported owning 2,323K shares, representing an increase of 58.34%. The firm increased its portfolio allocation in ALVR by 288.04% over the last quarter.
Alkeon Capital Management holds 4,923K shares representing 5.44% ownership of the company. In it's prior filing, the firm reported owning 2,754K shares, representing an increase of 44.06%. The firm increased its portfolio allocation in ALVR by 268.73% over the last quarter.
Gmt Capital holds 2,759K shares representing 3.05% ownership of the company. No change in the last quarter.
Acap Strategic Fund holds 2,467K shares representing 2.73% ownership of the company. In it's prior filing, the firm reported owning 1,368K shares, representing an increase of 44.55%. The firm increased its portfolio allocation in ALVR by 295.83% over the last quarter.
FDGRX - Fidelity Growth Company Fund holds 2,158K shares representing 2.39% ownership of the company. In it's prior filing, the firm reported owning 2,232K shares, representing a decrease of 3.44%. The firm decreased its portfolio allocation in ALVR by 1.29% over the last quarter.
AlloVir Background Information
(This description is provided by the company.)
AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened immune systems. The company’s innovative and proprietary technology platforms leverage off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viruses for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. AlloVir’s technology and manufacturing process enables the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
